Here's Why Exact Sciences ( EXAS ) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exact Sciences ( EXAS ) Just Flashed Golden Cross Signal: Do You Buy?
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
DGX's Haystack Oncology Teams Up With Rutgers Cancer Institute
Quest Diagnostics' Haystack Oncology joins Rutgers Cancer Institute to study how its ctDNA MRD test can guide therapy for stage II/III lung cancer.
This Cancer Detection Pioneer Is Worth a Look
Multicancer detection tests are closing in on FDA approval and potentially major sales.
Why Exact Sciences ( EXAS ) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Peering Into Exact Sciences's Recent Short Interest - Exact Sciences ( NASDAQ:EXAS )
Exact Sciences's EXAS short interest as a percent of float has fallen 22.42% since its last report. According to exchange reported data, there are now 7.34 million shares sold short, which is 4.43% of all regular shares that are available for trading.
Why Exact Sciences ( EXAS ) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Is Kodiak Sciences ( KOD ) Down 1.2% Since Last Earnings Report?
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Exact Sciences Launches Cancerguard MCED Blood Test, Stock Climbs
EXAS introduces Cancerguard, a blood test that detects more than 50 cancers, sending shares up after its U.S. debut.
Should You Continue to Hold EXAS Stock in Your Portfolio?
Exact Sciences sees growth in Cologuard and Oncotype DX, but rising costs and tough competition weigh on EXAS shares.
What's Fueling Tempus AI's Q2 Net Loss Improvement Momentum?
TEM's Q2 net loss narrows sharply, driven by surging genomics revenues, higher gross profits and tighter cost controls.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
TMO Receives FDA Approval for Oncomine Dx Target Test
Thermo Fisher secures FDA approval for its Oncomine Dx Target Test to identify NSCLC patients eligible for HERNEXEOS treatment.
Cathie Wood's Thursday Bet: ARK Just Bought $31 Million Worth Of Falling Deere Stock, Also Loads Up On Block, Robinhood Shares - ARK Innovation ETF ( BATS:ARKK )
Ark Invest, led by Cathie Wood, made significant trades on Thursday - focusing on Deere & Co. DE, Block Inc. XYZ and Robinhood Markets Inc. HOOD. ArrivedBuy shares of homes and vacation rentals for as little as $100. Get Started WiserAdvisorGet matched with a trusted, local financial advisor for ...
TEM Once Again Raises Its 2025 Sales Guidance: What's Driving the Move?
Tempus AI raises 2025 revenue outlook again after strong Q2 growth in genomics and AI-driven oncology solutions.
Micron To Rally More Than 49%? Here Are 10 Top Analyst Forecasts For Tuesday - Enbridge ( NYSE:ENB ) , Ballard Power Systems ( NASDAQ:BLDP )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Goldman Sachs cut ZipRecruiter, Inc. ZIP price target from $7 to $5.
EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up
Exact Sciences tops on Q2 earnings and revenue estimates and raises the 2025 outlook, but shares slide 8% after results.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The rock-star money manager is making the most of sell-offs in some of her stocks.
Here's Why Exact Sciences ( EXAS ) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Top 3 Health Care Stocks That Are Preparing To Pump This Month - Exact Sciences ( NASDAQ:EXAS ) , Outset Medical ( NASDAQ:OM )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates
Ironwood shares jump 9.3% as second-quarter earnings and revenues top estimates. The company maintains its 2025 outlook.
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues
Puma Biotechnology tops second-quarter earnings and revenue estimates as rising Nerlynx sales drive growth.
Cathie Wood Buys the Airbnb Dip With $21.5 Million Stock Purchase, Dumps Palantir, DraftKings And Robinhood Shares - ARK Fintech Innovation ETF ( BATS:ARKF ) , Airbnb ( NASDAQ:ABNB )
On Thursday, Cathie Wood-led Ark Invest executed significant trades involving Airbnb Inc. ABNB, Robinhood Markets Inc. HOOD, Palantir Technologies Inc. PLTR, and DraftKings Inc. DKNG. These trades reflect Ark's strategic adjustments in response to recent market developments and company-specific ...
Why Is Exact Sciences Stock Tumbling Thursday? - Exact Sciences ( NASDAQ:EXAS )
Q2 EPS loss of $0.01 beats estimate of $0.19; revenue jumps 16% to $811.1 million vs $774.3 million expected Exact Sciences ups FY25 revenue outlook to $3.13-$3.17 billion; screening sales forecast lifted to $2.44-$2.47 billion. Get special access to three exclusive "Top 10 Stocks" power lists ...
Exact Sciences ( EXAS ) Upgraded to Strong Buy: What Does It Mean for the Stock?
Exact Sciences (EXAS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
Mirum surges after second-quarter earnings and revenues top estimates, driven by Livmarli growth and a raised 2025 outlook.
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - ADMA Biologics ( NASDAQ:ADMA ) , Airbnb ( NASDAQ:ABNB )
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Thursday. Shares of Redwire Corporation RDW fell sharply in pre-market trading after the company reported worse-than-expected second-quarter financial results and cut its FY25 sales guidance.
Exact Sciences ( EXAS ) Surpasses Q2 Earnings and Revenue Estimates
Exact Sciences (EXAS) delivered earnings and revenue surprises of +1,200.00% and +4.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences ( EXAS ) Q2 Revenue Up 16%
Exact Sciences ( NASDAQ:EXAS ) , a leading provider of cancer screening and diagnostic tests, reported its Q2 2025 earnings on August 6, 2025. Revenue and GAAP earnings both exceeded analyst expectations, as new products and improved commercial execution powered performance above consensus ...
Foghorn Therapeutics Inc. ( FHTX ) Reports Q2 Loss, Lags Revenue Estimates
Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of +9.68% and -0.85%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?
VTRS braces for Q2 results as branded drug growth in Europe and China offsets generic headwinds in North America.
Zimmer Biomet to Report Q2 Earnings: Here's What to Expect
ZBH's Q2 results may show strength in Hips, Knees, and S.E.T. despite a projected year-over-year earnings dip.
TG Therapeutics ( TGTX ) Misses Q2 Earnings Estimates
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -46.88% and +3.75%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zoetis Gears Up to Report Q2 Earnings: Here's What to Expect
ZTS eyes an earnings beat as companion animal drugs like Simparica Trio and Apoquel are expected to drive Q2 revenue gains.
Will Healthcare Growth Help STE Beat on Q1 Earnings?
STERIS is likely to have experienced a strong Q1 with 14.3% EPS growth as Healthcare and AST segments show solid momentum.
Perrigo to Report Q2 Earnings: What's in Store for the Stock?
PRGO eyes Q2 results, which are likely to show sales of $1.08 billion, as investors await updates on its Kairos deal and macro pressures.
Exact Sciences ( EXAS ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River Q2 Earnings Preview: What's in Store for the Stock?
CRL gears up for Q2 earnings with expected revenue and EPS declines amid mixed segment performance.
Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
VRTX eyes second-quarter growth with surging Trikafta sales. Investors' focus is likely to be on the progress of Casgevy, and Alyftrek and Journavx launches.
Moderna to Report Q2 Earnings: Is a Beat in Store for the Stock?
MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline milestones.
Henry Schein to Report Q2 Earnings: What's in Store for the Stock?
HSIC eyes modest Q2 gains, with dental, medical and specialty segments showing signs of steady momentum.
KROS vs. EXAS: Which Stock Should Value Investors Buy Now?
KROS vs. EXAS: Which Stock Is the Better Value Option?
CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?
CRSP investors await the company's Q2 results with a focus on Casgevy sales growth and updates on gene-editing pipeline progress.
Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
ALT readies Q2 report as investors await fresh updates on pemvidutide program in obesity and liver disease studies.
HOLX vs. EXAS: Which Cancer Diagnostics Stock Should You Retain Now?
EXAS gains edge over HOLX as rising Cologuard adoption, new launches and bullish EPS trends boost investor appeal.
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
AMRN braces up for second-quarter results as U.S. Vascepa sales are likely to slide, while growth in the EU looks imminent.
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
INCY eyes strong Q2 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
Why Exact Sciences ( EXAS ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
With no revenue expected, VKTX's Q2 report is likely to have the spotlight on pipeline moves across its obesity drugs.
